SEARCH WITHIN CONTENT
VOLUME 24 , ISSUE 11 ( November, 2020 ) > List of Articles
Lakshmi Shobhavat, Rekha Solomon, Sudha Rao, Isha Bhagat, Sanjay Prabhu, Shakuntala Prabhu, Manoj Chandrakar
Keywords : Antibody, COVID-19, Intensive care, MIS-C, PICU, PIMS-TS, Refractory shock, SARS-CoV2
Citation Information : Shobhavat L, Solomon R, Rao S, Bhagat I, Prabhu S, Prabhu S, Chandrakar M. Multisystem Inflammatory Syndrome in Children: Clinical Features and Management—Intensive Care Experience from a Pediatric Public Hospital in Western India. Indian J Crit Care Med 2020; 24 (11):1089-1094.
License: CC BY-NC 4.0
Published Online: 16-12-2020
Copyright Statement: Copyright © 2020; The Author(s).
Background: Multisystem inflammatory syndrome (MIS) associated with severe acute respiratory syndrome coronavirus (SARS-CoV-2) (MIS-C) in children is being increasingly reported across the world. Materials and methods: Children fulfilling the World Health Organization criteria of MIS-C needing pediatric intensive care unit between April 15 and July 26, 2020 were studied. Results: There were 21 patients with median age of 7 years [interquartile range (IQR) 1.9–12.1], of which 11 were females. SARS-CoV-2 real-time polymerase chain reaction positive in 8/21 and/or antibody positive 16/21. Fever was present in all patients, and gastrointestinal symptoms being second most frequent (16/21). One child had aplastic anemia, while the rest had no comorbidities. Nearly all presented with shock (n = 20/21) and 90% needed vasoactive drugs with a median Vasoactive Inotropic Score of 40 (IQR 20–95). Thirteen children needed ventilatory support and one needed peritoneal dialysis. Nine children had left ventricular dysfunction and five had dilatation of coronaries on echocardiography. Inflammatory markers C-reactive protein [98 mg/dL (IQR 89–119)], serum ferritin [710 mg/dL (IQR 422–1,609)], and serum interleukin-6 levels [215 ng/L (IQR 43–527)] were uniformly elevated. Eighteen children received pulse methyl-prednisolone, eleven intravenous immunoglobulins, and four tocilizumab. Eighteen children (86%) were discharged home while three died. Conclusion: In our cohort, MIS-C was seen in previously healthy children with fever, gastrointestinal symptoms, and shock. Early and aggressive management of shock and immune modulation with methyl-prednisolone and intravenous immunoglobulin were used.
© Jaypee Brothers Medical Publishers (P) LTD.